Compare BioNano Genomics Inc (BNGO) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Macy's Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Macy's Inc trades at $24.53 (market cap $6.45B). The key difference: Macy's Inc is far larger — about 472.2× BioNano Genomics Inc's market cap, and Macy's Inc pays a 3.12% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | M | |
|---|---|---|
Market Cap | $13.66M | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $26.21 |
52-Week Low | $1.06 | $12.73 |
Enterprise Value | $16.26M | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Macy's (M) trades at $24.9, down 1.97% on the day, with a bullish technical signal and strong earnings beat history. The company shows improving fundamentals with net income margin recovery to 2.94% and positive cash flow trends. Recent institutional buying and analyst coverage reflects growing confidence in the turnaround strategy, though revenue declines remain a concern.
The stock presents value opportunity with attractive valuation multiples (P/E 10.13, P/S 0.3) and dividend yield. Upside potential exists to the $30 analyst target, but risks include ongoing revenue pressure and competitive retail environment. The successful execution of 'Bold New Chapter' strategy remains critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
